Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in ...
INDIGO is the largest clinical trial conducted in patients living with IgG4-RD--Topline INDIGO results expected by the end of 2025-WALTHAM, ...